These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34802864)

  • 1. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
    Fizazi K; González Mella P; Castellano D; Minatta JN; Rezazadeh Kalebasty A; Shaffer D; Vázquez Limón JC; Sánchez López HM; Armstrong AJ; Horvath L; Bastos DA; Amin NP; Li J; Unsal-Kacmaz K; Retz M; Saad F; Petrylak DP; Pachynski RK
    Eur J Cancer; 2022 Jan; 160():61-71. PubMed ID: 34802864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
    Fizazi K; Retz M; Petrylak DP; Goh JC; Perez-Gracia J; Lacombe L; Zschäbitz S; Burotto M; Mahammedi H; Gravis G; Bastos DA; McCune SL; Vázquez Limón JC; Kwan EM; Castellano D; Fléchon A; Saad F; Grimm MO; Shaffer DR; Armstrong AJ; Bhagavatheeswaran P; Amin NP; Ünsal-Kaçmaz K; Wang X; Li J; Loehr A; Pachynski RK
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35977756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
    Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
    Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
    Caffo O; Ortega C; Nolè F; Gasparro D; Mucciarini C; Aieta M; Zagonel V; Iacovelli R; De Giorgi U; Facchini G; Veccia A; Palesandro E; Verri E; Buti S; Razzini G; Bozza G; Maruzzo M; Ciccarese C; Schepisi G; Rossetti S; Maines F; Kinspergher S; Fratino L; Ermacora P; Nicodemo M; Giordano M; Sartori D; Scapoli D; Sabbatini R; Lo Re G; Morelli F; D'Angelo A; Vittimberga I; Lippe P; Carrozza F; Messina C; Galli L; Valcamonico F; Porta C; Pappagallo G; Aglietta M
    Eur J Cancer; 2021 Sep; 155():56-63. PubMed ID: 34358777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
    Heath E; Heilbrun L; Mannuel H; Liu G; Lara P; Monk JP; Flaig T; Zurita A; Mack P; Vaishampayan U; Stella P; Smith D; Bolton S; Hussain A; Al-Janadi A; Silbiger D; Usman M; Ivy SP
    Oncologist; 2019 Sep; 24(9):1149-e807. PubMed ID: 31152080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
    Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
    de Kouchkovsky I; Rao A; Carneiro BA; Zhang L; Lewis C; Phone A; Small EJ; Friedlander T; Fong L; Paris PL; Ryan CJ; Szmulewitz RZ; Aggarwal R
    Clin Cancer Res; 2022 Apr; 28(8):1531-1539. PubMed ID: 35176163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
    George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
    Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
    Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
    Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
    J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
    Morris MJ; Loriot Y; Sweeney CJ; Fizazi K; Ryan CJ; Shevrin DH; Antonarakis ES; Pandit-Taskar N; Deandreis D; Jacene HA; Vesselle H; Petrenciuc O; Lu C; Carrasquillo JA; Higano CS
    Eur J Cancer; 2019 Jun; 114():107-116. PubMed ID: 31082669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial.
    Nguyen CB; Reimers MA; Perera C; Abida W; Chou J; Feng FY; Antonarakis ES; McKay RR; Pachynski RK; Zhang J; Reichert ZR; Palmbos PL; Caram MEV; Vaishampayan UN; Heath EI; Hopkins AC; Cieslik MP; Wu YM; Robinson DR; Baladandayuthapani V; Chinnaiyan AM; Alva AS
    Clin Cancer Res; 2024 Aug; 30(15):3200-3210. PubMed ID: 38787530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
    Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
    Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
    Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
    Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
    Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
    Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.